Opti-Mol Consulting, LLC provides medicinal chemistry and drug discovery consulting services for preclinical drug discovery programs. The Principal Consultant and Founder is Dr. Brad Henke, an accomplished scientist with over 23 years of experience in the pharmaceutical industry. Prior to establishing Opti-Mol Consulting, Dr. Henke was a Director of Chemistry at GlaxoSmithKline (GSK) in Research Triangle Park, North Carolina, where he was accountable for leading medicinal chemistry divisions in both metabolic diseases (e.g. diabetes, obesity) and skeletal muscle diseases. Dr. Henke has a strong background in organic and medicinal chemistry, drug discovery program leadership, technical due diligence work, and strategic planning of preclinical research programs from initial lead generation through Phase Ib/2a clinical trials. He has knowledge and experience in structure- and fragment-based drug design, pharmacophore mapping, structure-activity relationship analysis, chemoproteomics, in vitro and cell-based screening, in vivo pharmacology, pharmacokinetics, non-clinical toxicology, and has experience with both small molecule- and peptide-based discovery programs.